NASHVILLE, Tenn. & PALO ALTO, Calif.--(BUSINESS WIRE)--Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), which offers cutting-edge clinical research alongside integrated cancer services, and Syapse, the leading provider of precision medicine software, announced plans today to launch a precision oncology clinical service collaboration. The software-based service is designed to support Sarah Cannon’s efforts to make tumor genome profiling a key component of the care continuum for the more than 100,000 newly diagnosed cancer patients seen annually across its network of cancer centers throughout the United States and United Kingdom.
Leaders from both organizations served on a panel to discuss genomic profiling in routine clinical care at the Personalized Medicine World Conference in Mountain View, Calif. on January 27. The precision oncology platform, to be launched in the second half of 2015, will assist in treatment planning and clinical decision-making by enabling Sarah Cannon care providers access to genomic testing, best practice guidelines and decision support. It will also allow Sarah Cannon’s personalized medicine team to streamline genomic data analysis to improve patient outcomes and expand clinical trial options for patients.
“Our research, care, and drug development initiatives to advance precision medicine in cancer are further enhanced through the use of the Syapse software platform,” said Howard A. “Skip” Burris III, MD, President, Clinical Operations for Sarah Cannon. “Combining clinical history, treatments, genomics, outcomes, and other relevant data within one system will help our physicians and researchers more rapidly identify patterns in patient data that support the development of personalized treatment plans for patients.”
In addition to assisting with treatment plans that are tailored to the individual patient, this integrated software is designed to support the growth of Sarah Cannon’s already extensive clinical trial menu by matching the latest clinical trial options with patients who are profiled in the system.
“Integrating genomic data with a patient’s cancer medical record to impact treatment decisions at Sarah Cannon’s scale has been an important goal of health systems since the inception of the Human Genome Project,” said Jonathan Hirsch, Founder and President of Syapse. “By leveraging Sarah Cannon’s international reach, the Syapse software platform will help in transforming today’s cancer care, and accelerate the development of novel therapies for tomorrow’s patients.”
About Sarah Cannon
Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), offers cutting-edge clinical research alongside integrated cancer services. From discovery to recovery, Sarah Cannon provides patients convenient access to world-class cancer care with more than 75 accredited centers across the US and UK. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, more than 900 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, more than 500 clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the- art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
About Syapse
Syapse software enables healthcare providers to deploy precision medicine programs. Leading academic and community healthcare providers use the Syapse Precision Medicine Data Platform to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. Headquartered in Palo Alto, California, Syapse is backed by The Social+Capital Partnership and Safeguard Scientifics (NYSE:SFE). For more information, please visit www.syapse.com.
